JP2017517538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517538A5 JP2017517538A5 JP2016572302A JP2016572302A JP2017517538A5 JP 2017517538 A5 JP2017517538 A5 JP 2017517538A5 JP 2016572302 A JP2016572302 A JP 2016572302A JP 2016572302 A JP2016572302 A JP 2016572302A JP 2017517538 A5 JP2017517538 A5 JP 2017517538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- ring
- pyridazin
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- MPNAKLGQWGUYOO-UHFFFAOYSA-N C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC(=C1)F)C(=O)NC)F Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC(=C1)F)C(=O)NC)F MPNAKLGQWGUYOO-UHFFFAOYSA-N 0.000 claims 1
- JMXQSRJJPVLGLQ-UHFFFAOYSA-N C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC=C1)C(=O)N)F Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC(=CC=C1)C(=O)N)F JMXQSRJJPVLGLQ-UHFFFAOYSA-N 0.000 claims 1
- CHIRBXJNJJPPBZ-UHFFFAOYSA-N C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC=C2CN(C(C2=C1)=O)C)F Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C1=CC=C2CN(C(C2=C1)=O)C)F CHIRBXJNJJPPBZ-UHFFFAOYSA-N 0.000 claims 1
- AZSCZGPLVZULKG-UHFFFAOYSA-N C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1)=O)C)F Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1)=O)C)F AZSCZGPLVZULKG-UHFFFAOYSA-N 0.000 claims 1
- XPSAGIQSESMIJK-UHFFFAOYSA-N C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1OC)=O)C)F Chemical compound C(C)N1C=NC2=C1N=NC=C2C=1C=CC(=C(C=1)C=1C=C2CN(C(C2=CC=1OC)=O)C)F XPSAGIQSESMIJK-UHFFFAOYSA-N 0.000 claims 1
- ZBZGITBHHLRNSX-UHFFFAOYSA-N FC1=C(C=C(C=C1)C=1C2=C(N=NC=1)N(C=N2)C(C)C)C=1C=C2CN(C(C2=CC=1)=O)C Chemical compound FC1=C(C=C(C=C1)C=1C2=C(N=NC=1)N(C=N2)C(C)C)C=1C=C2CN(C(C2=CC=1)=O)C ZBZGITBHHLRNSX-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462011137P | 2014-06-12 | 2014-06-12 | |
US62/011,137 | 2014-06-12 | ||
PCT/IB2015/054200 WO2015189744A1 (en) | 2014-06-12 | 2015-06-03 | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017517538A JP2017517538A (ja) | 2017-06-29 |
JP2017517538A5 true JP2017517538A5 (US07585860-20090908-C00112.png) | 2018-07-12 |
JP6491679B2 JP6491679B2 (ja) | 2019-03-27 |
Family
ID=53434408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016572302A Active JP6491679B2 (ja) | 2014-06-12 | 2015-06-03 | Gabaa受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 |
Country Status (6)
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3324961A4 (en) | 2015-07-17 | 2019-03-13 | Ovid Therapeutics, Inc. | METHOD FOR TREATING DEVELOPMENT DISORDERS WITH GABOXADOL |
EP3386983A1 (en) | 2015-12-10 | 2018-10-17 | Pfizer Limited | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain |
WO2018003691A1 (ja) * | 2016-06-28 | 2018-01-04 | 東レ株式会社 | エポキシ樹脂組成物、プリプレグおよび繊維強化複合材料 |
EP3481387A4 (en) * | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
EP3982937A4 (en) * | 2019-07-15 | 2022-08-10 | Ovid Therapeutics Inc. | PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT |
US20220387429A1 (en) * | 2019-10-21 | 2022-12-08 | Sk Biopharmaceuticals Co., Ltd. | Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability |
CN114981266A (zh) * | 2019-10-22 | 2022-08-30 | 纽罗塞克医疗公司 | Gabaa正向变构调节剂化合物、其制备方法和用途 |
WO2021081357A1 (en) * | 2019-10-23 | 2021-04-29 | Neurocycle Therapeutics, Inc. | Treatment of epileptic conditions with gabaa receptor modulators |
CN116693555A (zh) * | 2022-02-25 | 2023-09-05 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
WO2023213198A1 (zh) * | 2022-05-04 | 2023-11-09 | 华东师范大学 | 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂 |
CN117069725A (zh) * | 2022-05-10 | 2023-11-17 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
GB9921150D0 (en) * | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
AU1253002A (en) | 2000-11-10 | 2002-05-21 | Merck Sharp & Dohme | Imidazo-triazine derivatives as ligands for gaba receptors |
GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
EP1838152A2 (en) * | 2005-01-21 | 2007-10-03 | Neurogen Corporation | Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives |
EP1995241B1 (en) | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
RS53941B1 (en) | 2009-01-12 | 2015-08-31 | Pfizer Limited | SULFONAMID DERIVATIVES |
SG175090A1 (en) | 2009-05-07 | 2011-11-28 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
-
2015
- 2015-06-03 WO PCT/IB2015/054200 patent/WO2015189744A1/en active Application Filing
- 2015-06-03 EP EP15730284.5A patent/EP3154979B1/en not_active Not-in-force
- 2015-06-03 US US15/316,552 patent/US9802945B2/en active Active
- 2015-06-03 JP JP2016572302A patent/JP6491679B2/ja active Active
- 2015-06-03 ES ES15730284.5T patent/ES2664810T3/es active Active
- 2015-06-03 CA CA2951497A patent/CA2951497C/en not_active Expired - Fee Related